Final-Program-ATS-2023-AP.vp

SUNDAY • MAY 21

117

818 Effect of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis and Differing Extents of Emphysema on HRCT/ V. Cottin, Lyon, France 819 Immunosuppressive Treatment in Interstitial Lung Disease Secondary to Antisynthetase Syndrome and Systemic Sclerosis - a Multicenter Observational Study/ O. Freund, Tel Aviv, Israel 820 Steroid Therapy in Acute Exacerbations of Fibrotic Interstitial Lung Disease/ K. Koshy, Melbourne, Australia 821 Conventional Hypersensitivity Pneumonitis Management Vs the Addition of Antifibrotic Therapy: Does It Slow Disease Progression?/ S. Shah, Maywood, IL 822 Genomic Classifier for Usual Interstitial Pneumonia Predicts Progression in Fibrotic Lung Disease Across a Range of Clinical Diagnoses/ L.H. Lancaster, Nashville, TN 823 Endobronchial Optical Coherence Tomography Imaging as a Novel Method to Detect and Monitor Microscopic Disease Progression in IPF/ L.P. Hariri, Boston, MA A103 TOWARDS IMPROVING ICU PRACTICE 2:15 p.m. - 4:15 p.m. Marriott Marquis Washington Marquis Ballroom, Salons 9-10 (Level M2) Poster Viewing 2:15-3:00 Discussion 3:00-4:15 Chairing: H.B. Gershengorn, MD, FCCM, ATSF, Miami, FL S.M. Bagshaw, MD, MSc, Edmonton, Canada A.J. Admon, MD, MPH, MS, Ann Arbor, MI 1001 Lactation Practices and Breastfeeding in the Critically Ill Adult Patient/ K. Kolbe, Ann Arbor, MI 1002 Restrictive Versus Liberal Oxygen Targets in Post Cardiac Arrest Patients - Meta Analysis of Randomized Controlled Trials/ S. Singh, Baltimore, MD 1003 A Systematic Review and Meta-analysis Comparing the Mortality in Aggressive Versus Moderate Fluid Hydration for Acute Pancreatitis: A Paradigm Shift?/ R. Ali, Harrisburg, PA 1004 Extracorporeal Membrane Oxygenation (ECMO) Utilization in the Emergency Cardio-pulmonary Disorders - An Estimate of Pre-COVID-19 Era/ N. Abdi, Beijing, China CLINICAL POSTER DISCUSSION SESSION

804 Relationship of Sarcopenia and Frailty in Patients With Outcomes in Idiopathic Pulmonary Fibrosis/ M. Sridhar, Birmingham, AL 805 Body Mass Index Is Associated With Clinical Outcome in Patients With Idiopathic Pulmonary Fibrosis: A Nationwide Population-based Study/ H.-Y. Yoon, Seoul, Korea, Republic of 806 Clinical Impact of Weight Loss on Mortality in Patients With Idiopathic Pulmonary Fibrosis: A Retrospective Cohort Study/ J.K. Lee, Seoul, Korea, Republic of 807 Associations Between L-PF Questionnaire Dyspnea Scores and Outcomes in Patients With Progressive Fibrosing ILDs: Data From the INBUILD Trial/ M. Wijsenbeek, Rotterdam, Netherlands 808 External Validation and Longitudinal Application of a Multidimensional Index to Individualize Survival Prediction in Idiopathic Pulmonary Fibrosis/ A. Chandel, Bethesda, MD 809 New Prognostic Scoring System for Mortality in Idiopathic Pulmonary Fibrosis by Modifying the Gender, Age, and Physiology Model With Desaturation During the Six-minute Walk Test/ J.H. Jang, Busan, Korea, Republic of 810 Derivation of Multidimensional Index for Predicting Progression in Fibrotic Interstitial Lung Diseases and Comparison With Criteria Suggested by INBUILD and ATS/ERS-2022/ S.A. Cordero Da Silva, Sao Paulo, Brazil 811 Clinical and Epidemiological Characteristics of Patients Admitted With Idiopathic Pulmonary Fibrosis Exacerbation, a Nationwide Study/ M. El Labban, Mankato, MN 812 Identification of Factors Associated With Acute Respiratory Failure in Patients With Interstitial Lung Disease/ T. Ozlu, Trabzon, Turkey 813 Monocyte Count and Transplant-free Survival in Patients With Fibrotic Interstitial Lung Disease/ B. Min, Calgary, Canada 814 Differences in Serum Protein Expression by Sex in Patients With Systemic Sclerosis Associated Interstitial Lung Disease/ G.C. Cerro Chiang, Los Angeles, CA 815 Factors Associated With Persistence With Antifibrotic Therapy in Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Pulmonary Fibrosis Foundation Patient Registry/ T. Kulkarni, Birmingham, AL 816 Real World Outcomes of Progressive Fibrosing Interstitial Lung Disease: Validity of Definition and the Efficacies of Antifibrotics/ T. Niitsu, Suita, Japan 817 Effect of Nintedanib on Decline in Forced Vital Capacity (FVC) in Patients With Combined Pulmonary Fibrosis and Emphysema: Data From the INBUILD Trial/ V. Cottin, Lyon, France

ATS 2023 • Washington, DC